FDA to Reconsider Ban on 12 Unproven Peptides Following RFK Jr.'s Advocacy
The Food and Drug Administration (FDA) has announced upcoming meetings to discuss the potential lifting of restrictions on 12 unproven peptides, which were previously banned in 2023 due to safety concerns. These meetings, scheduled for July and February 2027, come after pressure from Robert F. Kennedy Jr., the U.S. Secretary of Health and Human Services, who has been a vocal advocate for these substances. Despite the lack of new safety or efficacy data, Kennedy has pushed for the reconsideration of these peptides, which are often marketed online without evidence for various health benefits. The FDA's advisory panel, the Pharmacy Compounding Advisory Committee, currently lacks a full roster, with only three voting members and one industry representative, raising concerns about the thoroughness of the review process. 
